Liminatus Pharma, Inc. Class A Common Stock (LIMN)

No analyst coverage available

We don't have analyst ratings or price target data for Liminatus Pharma, Inc. Class A Common Stock yet. Coverage gaps are common for sub-$1B market caps and recently-listed names.